114 related articles for article (PubMed ID: 6127884)
41. Hemodynamic and myocardial metabolic effects of the beta-agonist prenalterol in ischemic left ventricular dysfunction.
Kirlin PC; Walton JA; Brymer JF; Beauman G; Pitt B
J Cardiovasc Pharmacol; 1984; 6(5):852-8. PubMed ID: 6209491
[TBL] [Abstract][Full Text] [Related]
42. Characterization of the beta-adrenoceptor of the adipose cell of the rat.
Tan S; Curtis-Prior PB
Int J Obes; 1983; 7(5):409-14. PubMed ID: 6139348
[TBL] [Abstract][Full Text] [Related]
43. Acute haemodynamic effects of oral prenalterol in severe heart failure.
Petch MC; Wisbey C; Ormerod O; Scott C; Goodfellow RM
Br Heart J; 1984 Jul; 52(1):49-52. PubMed ID: 6146324
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.
Sainsbury EJ; Fitzpatrick D; Ikram H; Nicholls MG; Espiner EA; Ashley JJ
Eur J Clin Pharmacol; 1985; 28(4):397-403. PubMed ID: 2863151
[TBL] [Abstract][Full Text] [Related]
45. Cardioselectivity of prenalterol and isoproterenol.
Jennings G; Bobik A; Oddie C; Hargreaves M; Korner P
Clin Pharmacol Ther; 1983 Dec; 34(6):749-57. PubMed ID: 6641090
[TBL] [Abstract][Full Text] [Related]
46. Pharmacological and clinical effects of prenalterol--a new inotropic beta-adrenoceptor stimulant. Proceedings of a symposium in Hamburg, December 5, 1980.
Acta Med Scand Suppl; 1982; 659():1-325. PubMed ID: 6127881
[No Abstract] [Full Text] [Related]
47. Prenalterol in symptomatic sinus node dysfunction.
Feleke E; Rydén L; Smedgård P; Westerling S
Am Heart J; 1985 Jan; 109(1):185-7. PubMed ID: 2857060
[No Abstract] [Full Text] [Related]
48. Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol.
Kenakin TP; Ferris RM
J Cardiovasc Pharmacol; 1983; 5(1):90-7. PubMed ID: 6186866
[TBL] [Abstract][Full Text] [Related]
49. Failure of beta-adrenergic stimulation to affect cholecystokinin-stimulated sigmoid motility in man.
Lyrenäs E; Abrahamsson H; Dotevall G
Scand J Gastroenterol; 1985 Dec; 20(10):1169-74. PubMed ID: 2869574
[TBL] [Abstract][Full Text] [Related]
50. Effects of beta-adrenoceptor stimulation on rectosigmoid motility in man.
Lyrenäs E; Abrahamsson H; Dotevall G
Dig Dis Sci; 1985 Jun; 30(6):536-40. PubMed ID: 2859970
[TBL] [Abstract][Full Text] [Related]
51. Noninvasive assessment of chronotropic and inotropic response to preferential beta-1 and beta-2 adrenoceptor stimulation.
Corea L; Bentivoglio M; Verdecchia P; Motolese M; Sorbini CA; Grassi V; Tantucci C
Clin Pharmacol Ther; 1984 Jun; 35(6):776-81. PubMed ID: 6145533
[TBL] [Abstract][Full Text] [Related]
52. Intrinsic sympathomimetic activity of the partial agonist prenalterol in relation to beta adrenoceptor interaction in various tissues, in vitro.
Mattsson H; Hedberg A; Carlsson E
J Pharmacol Exp Ther; 1983 Mar; 224(3):654-61. PubMed ID: 6131123
[TBL] [Abstract][Full Text] [Related]
53. Haemodynamic effects of prenalterol in patients on dialysis.
Lustenberger N
Acta Med Scand Suppl; 1982; 659():157-67. PubMed ID: 6127886
[TBL] [Abstract][Full Text] [Related]
54. Prenalterol, a non-selective beta-adrenoceptor ligand with absolute beta1-selective partial agonist activity.
Hedberg A; Mattsson H; Carlsson E
J Pharm Pharmacol; 1980 Sep; 32(9):660-1. PubMed ID: 6107374
[No Abstract] [Full Text] [Related]
55. Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure.
Leinberger H; Mäurer W; Haueisen H; Schuler G; Kübler W
Acta Med Scand Suppl; 1982; 659():299-306. PubMed ID: 6127896
[TBL] [Abstract][Full Text] [Related]
56. Role of cyclic AMP in cardiac beta-adrenoceptor desensitization: studies using prenalterol and inhibitors of phosphodiesterase.
Bobik A; Little PJ
J Cardiovasc Pharmacol; 1984; 6(5):795-801. PubMed ID: 6209482
[TBL] [Abstract][Full Text] [Related]
57. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Blachère JC; Pérusse F; Bukowiecki LJ
Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
[TBL] [Abstract][Full Text] [Related]
58. Haemodynamic effects of prenaterol and cardiac glycosides in patients with recent myocardial infarction.
Boström PA; Andersson J; Johansson BW; Lilja B; Thorell J; Tidfält K; Westerling S
Eur J Clin Invest; 1984 Jun; 14(3):175-80. PubMed ID: 6147253
[TBL] [Abstract][Full Text] [Related]
59. Prenalterol as a selective cardiostimulant: differences between organ and receptor selectivity.
Kenakin TP
J Cardiovasc Pharmacol; 1985; 7(1):208-10. PubMed ID: 2580145
[No Abstract] [Full Text] [Related]
60. On the stereospecificity of the beta2-adrenoceptor blocking properties of prenalterol.
Johansson U; Waldeck B
J Pharm Pharmacol; 1980 Sep; 32(9):659-60. PubMed ID: 6107373
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
